Trial · NCT04971226
Results by group314
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 314
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI | Asciminib (All Asciminib ) | 136 | Participants | ||
| Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI | Investigator Selected TKI (All Comparators) | 100 | Participants | ||
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Asciminib (All Asciminib ) | Complete cytogenetic response (CCyR) | 1 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Investigator Selected TKI (All Comparators) | Complete cytogenetic response (CCyR) | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Asciminib (All Asciminib ) | Partial cytogenetic response (PCyR) | 1 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Investigator Selected TKI (All Comparators) | Partial cytogenetic response (PCyR) | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Asciminib (All Asciminib ) | Minor cytogenetic response (mCyR) | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Investigator Selected TKI (All Comparators) | Minor cytogenetic response (mCyR) | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Asciminib (All Asciminib ) | Minimal cytogenetic response | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Investigator Selected TKI (All Comparators) | Minimal cytogenetic response | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Asciminib (All Asciminib ) | No cytogenetic response | 0 | Participants | |
| Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | Investigator Selected TKI (All Comparators) | No cytogenetic response | 0 | Participants | |
| Trough Plasma Concentrations. | Asciminib (All Asciminib ) | 161 | Full Range 11.9 to 1010 | ng/mL | |
| Pharmacokinetics (PK) of Asciminib: Cmax | Asciminib (All Asciminib) | 1470 | Geometric Coefficient of Variation 38.2 | ng/mL | |
| PK of Asciminib: Tmax | Asciminib (All Asciminib) | 2.00 | Full Range 0.883 to 3.18 | Hour (hr) | |
| PK of Asciminib: AUCtau and AUClast | Asciminib (All Asciminib) | AUClast | 8590 | Geometric Coefficient of Variation 42.2 | ng*hr/mL |
| PK of Asciminib: AUCtau and AUClast | Asciminib (All Asciminib) | AUCtau | NA | Geometric Coefficient of Variation NA | ng*hr/mL |
| PK of Asciminib: CL/F | Asciminib (All Asciminib) | NA | Geometric Coefficient of Variation NA | ng*hr/mL | |
| Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96 | Asciminib (All Asciminib ) | Global health status/QoL / Very much better | 10 | Participants | |
| Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96 | Investigator Selected TKI (All Comparators) | Global health status/QoL / Very much better | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04971226/results